Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Commission (EC) has approved KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination ...

Approval based on AZUR-1 data showing significant proportion of participants with no detectable signs of cancer one year or more after treatment ...

Explore how pembrolizumab blocks PD-1, why responses vary across cancers, and how PD-L1, MSI/dMMR, TMB, resistance, and ...

The guidelines incorporate cosibelimab for locally advanced cutaneous squamous cell carcinoma after favorable results in the CK-301-101 trial. The National Comprehensive Cancer Network (NCCN) has ...

News Source: Ophelia Keating. (October 16, 2026). New Landmark-Guided Surgery Lets Scientists Inject Genes Into Multiple ...

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Company will release its third quarter 2026 financial results before the market opens on ...

Nice to meet you. I run the "Anticancer Drug Encyclopedia."I am a practicing pharmacist and hold certifications and ...

A new case report describes a pembrolizumab-treated patient who developed primary hypothyroidism from immune thyroid ...

Merck’s Keytruda plus Padcev receives European Commission approval to treat adults with resectable muscle-invasive bladder cancer: Rahway, New Jersey Friday, October 23, 2026, 1 ...

FDA grants accelerated approval to GSK's Jemperli for stage II/III MSI-H or dMMR locally advanced rectal cancer. Read what this means for patients today.

Merck & Moderna to present positive results from phase 3 INTerpath-001 trial for intismeran autogene plus Keytruda at ESMO 2026 Presidential Symposium: Rahway, New Jersey Saturday ...

Sun Pharmaceutical's Unloxcyt is recommended in cancer care guidelines as a significant treatment option for locally advanced ...